Aslan Pharmaceuticals Ltd. (Singapore)

The Company is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients.
The Company's portfolio is led by eblasakimab (also known as ASLAN004), a potential first-in-class human monoclonal antibody that binds to the IL-13 receptor, blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13 which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. Eblasakimab has the potential to improve upon current biologics used to treat allergic disease.
The Company currently investigating eblasakimab as a therapeutic antibody for moderate-to-severe AD. In July 2023 it reported positive topline data from its Phase 2b TREK-AD study in moderate-to-severe AD, supporting eblasakimab's potential to deliver a monthly dosing regimen from initiation in AD. The Company is also investigating eblasakimab in dupilumab-experienced, moderate-to-severe AD patients in the Phase 2 trial, TREK-DX.
The Company is developing farudodstat (also known as ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a best-in-class therapy in autoimmune disease. Inhibition of DHODH is demonstrated to have anti-inflammatory and immunomodulatory effects that are selective towards rapidly proliferating lymphocytes, making it an attractive target for immune-mediated inflammatory diseases, such as alopecia areata (AA).
The Company hold global rights to all of its product candidates with the exception of (1) farudodstat, for which Kyungnam Biopharma (previously known as BioGenetics) acquired rights for the Republic of Korea (South Korea) and (2) eblasakimab, for which Zenyaku Kogyo Co., Ltd acquired rights for Japan.
The Company has only one reportable operating segment.
HISTORY
2014 The Company was incorporated in the Cayman Islands on June 23 2014.
2017 The Company/s ordinary shares traded on the TPEx under “6497” from June 1, 2017 to August 25, 2020.
2018 the Company s ADSs began trading on The Nasdaq Global Market on May 4, 2018, under the trading symbol “ASLN”.
2020 The Company was delisted on September 16, 2020.
2022 On September 29, 2022, the Company transferred to The Nasdaq Capital Market and continued trading under the same trading symbol “ASLN”.